0001628280-24-011003.txt : 20240313
0001628280-24-011003.hdr.sgml : 20240313
20240313173535
ACCESSION NUMBER: 0001628280-24-011003
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240311
FILED AS OF DATE: 20240313
DATE AS OF CHANGE: 20240313
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rodman David Malcom
CENTRAL INDEX KEY: 0001672659
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41614
FILM NUMBER: 24747147
MAIL ADDRESS:
STREET 1: 3122 STERLING CIRCLE
STREET 2: SUITE 200
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mineralys Therapeutics, Inc.
CENTRAL INDEX KEY: 0001933414
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 150 N. RADNOR CHESTER ROAD
STREET 2: SUITE F200
CITY: RADNOR
STATE: PA
ZIP: 19087
BUSINESS PHONE: (888) 378-6240
MAIL ADDRESS:
STREET 1: 150 N. RADNOR CHESTER ROAD
STREET 2: SUITE F200
CITY: RADNOR
STATE: PA
ZIP: 19087
4
1
wk-form4_1710365726.xml
FORM 4
X0508
4
2024-03-11
0
0001933414
Mineralys Therapeutics, Inc.
MLYS
0001672659
Rodman David Malcom
150 N. RADNOR CHESTER ROAD,
SUITE F200
RADNOR
PA
19087
0
1
0
0
Chief Medical Officer
0
Common Stock
2024-03-11
4
M
0
5017
0.54
A
49283
D
Common Stock
2024-03-12
4
M
0
6348
1.08
A
55631
D
Stock Option
0.54
2024-03-11
4
M
0
5017
0
D
2031-03-11
Common Stock
5017
50173
D
Stock Option
1.08
2024-03-12
4
M
0
6348
0
D
2031-07-11
Common Stock
6348
209503
D
Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.
The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.
Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.
The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.
/s/ Adam Levy, Attorney-in-fact
2024-03-13